CA2289117A1 - Procede et construction pouvant inhiber une migration cellulaire - Google Patents
Procede et construction pouvant inhiber une migration cellulaire Download PDFInfo
- Publication number
- CA2289117A1 CA2289117A1 CA002289117A CA2289117A CA2289117A1 CA 2289117 A1 CA2289117 A1 CA 2289117A1 CA 002289117 A CA002289117 A CA 002289117A CA 2289117 A CA2289117 A CA 2289117A CA 2289117 A1 CA2289117 A1 CA 2289117A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- domain
- acid molecule
- recombinant nucleic
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000013152 negative regulation of cell migration Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 58
- 239000013598 vector Substances 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 40
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 40
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 40
- 108020003175 receptors Proteins 0.000 claims abstract description 38
- 102000005962 receptors Human genes 0.000 claims abstract description 38
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 25
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
- 210000001519 tissue Anatomy 0.000 claims abstract description 19
- 230000012292 cell migration Effects 0.000 claims abstract description 16
- 238000010361 transduction Methods 0.000 claims abstract description 16
- 230000026683 transduction Effects 0.000 claims abstract description 16
- 238000001890 transfection Methods 0.000 claims abstract description 14
- 239000012636 effector Substances 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 12
- 238000003780 insertion Methods 0.000 claims abstract description 10
- 230000037431 insertion Effects 0.000 claims abstract description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 9
- 230000015556 catabolic process Effects 0.000 claims abstract description 9
- 238000006731 degradation reaction Methods 0.000 claims abstract description 9
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 9
- 230000007838 tissue remodeling Effects 0.000 claims abstract description 9
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 7
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 6
- 230000002463 transducing effect Effects 0.000 claims abstract description 6
- 230000004709 cell invasion Effects 0.000 claims abstract description 4
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 3
- 239000013603 viral vector Substances 0.000 claims abstract description 3
- 239000003112 inhibitor Substances 0.000 claims description 24
- 241000701161 unidentified adenovirus Species 0.000 claims description 23
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 20
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 16
- 229960005356 urokinase Drugs 0.000 claims description 14
- 241000283690 Bos taurus Species 0.000 claims description 11
- 239000002753 trypsin inhibitor Substances 0.000 claims description 8
- 108010039627 Aprotinin Proteins 0.000 claims description 7
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 7
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 210000002889 endothelial cell Anatomy 0.000 claims description 7
- 239000013605 shuttle vector Substances 0.000 claims description 7
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 6
- 108010088854 urinastatin Proteins 0.000 claims description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 4
- 108010023795 VLDL receptor Proteins 0.000 claims description 4
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 230000003393 splenic effect Effects 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 229940122858 Elastase inhibitor Drugs 0.000 claims description 3
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 claims description 3
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 claims description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims description 3
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 3
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 claims description 3
- 239000003602 elastase inhibitor Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 2
- 241000696272 Gull adenovirus Species 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 46
- 239000012634 fragment Substances 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 24
- 101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 15
- 108010088842 Fibrinolysin Proteins 0.000 description 14
- 229940012957 plasmin Drugs 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 13
- 102000035195 Peptidases Human genes 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 238000010367 cloning Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 6
- 208000034827 Neointima Diseases 0.000 description 6
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 6
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000008692 neointimal formation Effects 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 5
- 210000002437 synoviocyte Anatomy 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 4
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002806 plasmin inhibitor Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 229940108519 trasylol Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 229940122791 Plasmin inhibitor Drugs 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100257820 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ssp-1 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003422 vasoregulatory effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une molécule d'acide nucléique recombinante qui comprend un vecteur convenant pour une transfection ou une transduction de cellules mammaliennes. Lesdits vecteurs contiennent une insertion d'acide nucléique qui code un polypeptide (ou une protéine) hybride pouvant être exprimé et comprend deux domaines ayant, l'un une fonction de fixation, et l'autre une fonction effectrice. Le domaine ayant une fonction de fixation peut comprendre un domaine de fixation d'un récepteur, et le domaine ayant une fonction effectrice peut avoir une activité enzymatique, en particulier une activité d'inhibition de protéase. Le vecteur peut être un vecteur viral (adénovirus ou rétrovirus) ou non viral convenant pour une transfection ou une transduction de cellules mammaliennes. L'insertion d'acide nucléique qui code un polypeptide (ou une protéine) hybride pouvant être exprimé peut être assujettie à un promoteur spécifique d'une cellule ou d'un tissu. On décrit en outre un processus destiné à prévenir une activité protéolytique locale, une dégradation matricielle extracellulaire, une migration cellulaire, une invasion cellulaire ou un remodelage tissulaire, l'opération consistant à transfecter ou transduire les cellules en cause ou des cellules dans leur environnement avec la molécule d'acide nucléique recombinante pour obtenir localement l'expression du polypeptide (ou de la protéine) hybride codé par ladite molécule. On décrit enfin un processus de production du polypeptide ou de la protéine hybride par transfection ou transduction de cellules mammaliennes avec la molécule d'acide nucléique recombinante pour obtenir l'expression du polypeptide (ou de la protéine) hybride ainsi produit, et éventuellement le récupérer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201423 | 1997-05-12 | ||
| EP97201423.7 | 1997-05-12 | ||
| PCT/NL1998/000259 WO1998051788A2 (fr) | 1997-05-12 | 1998-05-11 | Procede et construction pouvant inhiber une migration cellulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2289117A1 true CA2289117A1 (fr) | 1998-11-19 |
Family
ID=8228315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002289117A Abandoned CA2289117A1 (fr) | 1997-05-12 | 1998-05-11 | Procede et construction pouvant inhiber une migration cellulaire |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0981606A2 (fr) |
| JP (1) | JP2001525669A (fr) |
| AU (1) | AU7553698A (fr) |
| CA (1) | CA2289117A1 (fr) |
| NO (1) | NO995564L (fr) |
| NZ (1) | NZ500656A (fr) |
| WO (1) | WO1998051788A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4070499A (en) | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
| AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| DE10020125A1 (de) * | 2000-04-18 | 2001-10-25 | Friedrich Schiller Uni Jena Bu | Agens für den postoperativen Einsatz nach Entfernung von Knochentumoren |
| EP1903113A1 (fr) * | 2000-12-18 | 2008-03-26 | Arriva Pharmaceuticals, Inc. | Inhibiteurs de protéase multifonctionnels et leur utilisation dans le traitement de maladies |
| EP1366175B1 (fr) * | 2000-12-18 | 2008-01-23 | Arriva Pharmaceuticals, Inc. | Inhibiteurs de protease multifonctionnels et leur utilisation dans le traitement de maladies |
| US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| CA2461380C (fr) | 2001-10-11 | 2011-03-22 | Merck & Co., Inc. | Vaccin contre le virus de l'hepatite c |
| ES2344253T3 (es) * | 2001-10-11 | 2010-08-23 | MERCK SHARP & DOHME CORP. | Vacuna contra el virus de la hepatitis c. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) * | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5504001A (en) * | 1987-11-25 | 1996-04-02 | Zymogenetics, Inc. | Hybrid plasminogen activator |
| ATE133993T1 (de) * | 1989-02-17 | 1996-02-15 | Merck & Co Inc | Protein-antikrebsmittel |
| AU648505B2 (en) * | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| DK0404750T3 (da) * | 1989-05-26 | 1994-10-03 | Univ Washington | Vævsinhibitor for metalloproteaser |
| JPH05502880A (ja) * | 1989-12-22 | 1993-05-20 | セラジェン・インコーポレーテッド | トランスロケーション領域および細胞結合領域を有するハイブリッド分子 |
| CA2075974C (fr) * | 1990-02-15 | 2001-02-06 | Dana M. Fowlkes | Reactifs d'affinite entierement synthetiques |
| GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
| AU685187B2 (en) * | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
| WO1995013091A1 (fr) * | 1993-11-12 | 1995-05-18 | International Technology Management Associates, Ltd. | Procedes pour la reparation de tissu conjonctif |
| US5550213A (en) * | 1993-12-27 | 1996-08-27 | Rutgers, The State University Of New Jersey | Inhibitors of urokinase plasminogen activator |
| DK0739355T3 (da) * | 1994-01-11 | 2005-01-24 | Dyax Corp | Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf |
| AU2342995A (en) * | 1994-04-22 | 1995-11-16 | Jorgen Gliemann | Peptides binding to the alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US5843724A (en) * | 1995-04-27 | 1998-12-01 | Rutgers University | Chimeric nucleic acids and proteins for inhibiting HIV-1 expression |
| US5726050A (en) * | 1995-06-20 | 1998-03-10 | Massachusetts Institute Of Technology | Z-DNA binding protein and applications |
| US6509445B1 (en) * | 1996-01-08 | 2003-01-21 | Nissin Food Products Co., Ltd. | Cancerous metastasis inhibitor |
-
1998
- 1998-05-11 EP EP98923197A patent/EP0981606A2/fr not_active Withdrawn
- 1998-05-11 CA CA002289117A patent/CA2289117A1/fr not_active Abandoned
- 1998-05-11 AU AU75536/98A patent/AU7553698A/en not_active Abandoned
- 1998-05-11 WO PCT/NL1998/000259 patent/WO1998051788A2/fr not_active Application Discontinuation
- 1998-05-11 JP JP54907798A patent/JP2001525669A/ja not_active Ceased
- 1998-05-11 NZ NZ500656A patent/NZ500656A/en unknown
-
1999
- 1999-11-12 NO NO995564A patent/NO995564L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO995564D0 (no) | 1999-11-12 |
| JP2001525669A (ja) | 2001-12-11 |
| WO1998051788A2 (fr) | 1998-11-19 |
| AU7553698A (en) | 1998-12-08 |
| WO1998051788A3 (fr) | 1999-05-20 |
| EP0981606A2 (fr) | 2000-03-01 |
| NO995564L (no) | 2000-01-11 |
| NZ500656A (en) | 2001-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100188302B1 (ko) | 활성화피브린용해성과항-혈전성단백질 | |
| KR100291529B1 (ko) | 단백질 씨 유도체 | |
| US5256770A (en) | Oxidation resistant thrombomodulin analogs | |
| CA2298018C (fr) | Procedes et compositions pour inhiber l'angiogenese | |
| Baker et al. | Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells | |
| JP3087746B2 (ja) | キメラセリンプロテアーゼ | |
| Yokoyama et al. | Addition of an aminopeptidase N‐binding sequence to human endostatin improves inhibition of ovarian carcinoma growth | |
| US5491129A (en) | Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them | |
| JP2012135307A (ja) | Ｐａｉ−１機能の治療的阻害因子およびその使用法 | |
| CA2289117A1 (fr) | Procede et construction pouvant inhiber une migration cellulaire | |
| RU2143490C1 (ru) | Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство | |
| US5242688A (en) | Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants | |
| JP4733337B2 (ja) | ヒトのウロキナーゼ型プラスミノゲン活性化因子の遺伝子を含む組換えウイルスベクターおよび非ウイルスベクター、および肝線維症、腎線維症、肺線維症、膵線維症、心臓線維症などのさまざまなタイプの線維症、および肥厚性瘢痕の治療におけるその有用性 | |
| Rao et al. | Prokaryotic expression, purification, and reconstitution of biological activities (antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2 | |
| Holvoet et al. | Biochemical characterization of single‐chain chimeric plasminogen activators consisting of a single‐chain Fv fragment of a fibrin‐specific antibody and single‐chain urokinase | |
| CA2046906A1 (fr) | Analogues solubles de thrombomoduline | |
| Lee et al. | α2-antiplasmin: Potential therapeutic roles in fibrin survival and removal | |
| JP3329340B2 (ja) | トロンビン活性化プラスミノーゲン誘導体 | |
| Lamfers et al. | Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: inhibition of migration and visualization of expression | |
| JPH08231595A (ja) | 繊維素溶解性のトロンビン阻害性質を有するキメラたん白質 | |
| EP0416037A1 (fr) | Analogues de peroxide dismutase a proprietes de liaison inedites. | |
| KR970005046B1 (ko) | 개량형 조직 플라스미노겐 활성화 인자 | |
| CA2162986A1 (fr) | Proteines possedant des proprietes fibrinolytiques et anticoagulantes | |
| CA1341445C (fr) | Activateur tissulaire du plasminogene (t-pa) ameliore par la deletion du premier domaine kringle | |
| JP2000504941A (ja) | トロンビンによって活性化され得るプラスミノーゲンアクチベーター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |